Diop Mame-Kany, Molina Oscar Eduardo, Birlea Mirela, LaRue Hélène, Hovington Hélène, Têtu Bernard, Lacombe Louis, Bergeron Alain, Fradet Yves, Trudel Dominique
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (axe Cancer) and Institut du Cancer de Montréal, 900 Saint-Denis, Montréal, QC H2X 0A9, Canada.
Department of Pathology and Cellular Biology, Université de Montréal, 2900 Boulevard Édouard-Montpetit, Montréal, QC H3T 1J4, Canada.
Cancers (Basel). 2023 Apr 9;15(8):2217. doi: 10.3390/cancers15082217.
Intraductal carcinoma of the prostate (IDC-P) is an aggressive histological subtype of prostate cancer (PCa) detected in approximately 20% of radical prostatectomy (RP) specimens. As IDC-P has been associated with PCa-related death and poor responses to standard treatment, the purpose of this study was to explore the immune infiltrate of IDC-P. Hematoxylin- and eosin-stained slides from 96 patients with locally advanced PCa who underwent RP were reviewed to identify IDC-P. Immunohistochemical staining of CD3, CD8, CD45RO, FoxP3, CD68, CD163, CD209 and CD83 was performed. For each slide, the number of positive cells per mm in the benign tissues, tumor margins, cancer and IDC-P was calculated. Consequently, IDC-P was found in a total of 33 patients (34%). Overall, the immune infiltrate was similar in the IDC-P-positive and the IDC-P-negative patients. However, FoxP3 regulatory T cells ( < 0.001), CD68 and CD163 macrophages ( < 0.001 for both) and CD209 and CD83 dendritic cells ( = 0.002 and = 0.013, respectively) were less abundant in the IDC-P tissues compared to the adjacent PCa. Moreover, the patients were classified as having immunologically "cold" or "hot" IDC-P, according to the immune-cell densities averaged in the total IDC-P or in the immune hotspots. The CD68/CD163/CD209-immune hotspots predicted metastatic dissemination ( = 0.014) and PCa-related death ( = 0.009) in a Kaplan-Meier survival analysis. Further studies on larger cohorts are necessary to evaluate the clinical utility of assessing the immune infiltrate of IDC-P with regards to patient prognosis and the use of immunotherapy for lethal PCa.
前列腺导管内癌（IDC-P）是前列腺癌（PCa）的一种侵袭性组织学亚型，在约20%的根治性前列腺切除术（RP）标本中被检测到。由于IDC-P与PCa相关死亡及对标准治疗反应不佳有关，本研究旨在探索IDC-P的免疫浸润情况。回顾了96例行RP的局部晚期PCa患者的苏木精-伊红染色切片以识别IDC-P。进行了CD3、CD8、CD45RO、FoxP3、CD68、CD163、CD209和CD83的免疫组织化学染色。对于每张切片，计算良性组织、肿瘤边缘、癌组织和IDC-P中每毫米的阳性细胞数。结果，共在33例患者（34%）中发现了IDC-P。总体而言，IDC-P阳性和IDC-P阴性患者的免疫浸润情况相似。然而，与相邻的PCa相比，IDC-P组织中FoxP3调节性T细胞（<0.001）、CD68和CD163巨噬细胞（两者均<0.001）以及CD209和CD83树突状细胞（分别为=0.002和=0.013）的数量较少。此外，根据IDC-P总体或免疫热点区域的平均免疫细胞密度，将患者分为免疫“冷”或“热”的IDC-P。在Kaplan-Meier生存分析中，CD68/CD163/CD209免疫热点区域可预测转移扩散（=0.014）和PCa相关死亡（=0.009）。有必要对更大的队列进行进一步研究，以评估评估IDC-P免疫浸润对患者预后的临床实用性以及对致命性PCa使用免疫疗法的情况。
